Asterias Biotherapeutics Inc (AST) Set to Announce Quarterly Earnings on Monday
Asterias Biotherapeutics Inc (NYSE:AST) is set to announce its earnings results after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
Shares of Asterias Biotherapeutics Inc (NYSE AST) opened at 3.30 on Monday. The firm’s 50-day moving average is $3.49 and its 200 day moving average is $3.50. The stock’s market cap is $162.57 million. Asterias Biotherapeutics Inc has a 52-week low of $2.54 and a 52-week high of $5.80.
Several brokerages have commented on AST. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, July 17th.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/asterias-biotherapeutics-inc-ast-set-to-announce-quarterly-earnings-on-monday.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.